Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
WEB13 hours ago · Sept 30 (Reuters) - Bristol Myers Squibb (BMY.N) won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for the cancer ...
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets …
WEB3 days ago · Bristol Myers Squibb said Cobenfy gives patients an important new option to current schizophrenia therapy. Shares of Bristol Myers Squibb (BMY) rose Friday, a day after the Food and Drug ...
Bristol Myers Squibb - U.S. Food and Drug Administration …
WEB5 days ago · PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults. 1 COBENFY represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating ...
FDA approves Bristol Myers Squibb's schizophrenia drug
WEB4 days ago · The Food and Drug Administration approved Bristol Myers Squibb’s highly anticipated schizophrenia drug, the first novel type of treatment for the debilitating, chronic mental disorder in more ...
Bristol Myers Squibb - News
WEBSep 18, 2024 · U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
News - Bristol Myers Squibb
WEBStay updated on the latest news from Bristol Myers Squibb, a global biopharmaceutical company dedicated to developing and delivering innovative medicines for serious diseases.
Bristol Myers second-quarter results beat expectations, helped by …
WEBJul 26, 2024 · Drugmaker Bristol Myers Squibb posted better-than-expected second-quarter results, driven by growth from new products like anemia treatment Reblozyl and heart drug Camzyos as well as from its...
Bristol-Myers Squibb to acquire Mirati in up to $5.8 billion deal
WEBOct 8, 2023 · Bristol-Myers Squibb on Sunday said it will acquire cancer drugmaker Mirati Therapeutics for up to $5.8 billion, diversifying its oncology business and adding drugs it hopes can help offset...
Pharmaceutical press releases & news - Bristol Myers Squibb
WEBSep 15, 2024 · Explore Bristol Myers Squibb's latest press releases to learn more about our company, our medicines and research innovation, our partnerships, our people, and our Foundation efforts as we work to support patients fighting serious disease.
Bristol Myers to Acquire the Drugmaker Karuna for $14 Billion
WEBDec 22, 2023 · Bristol Myers Squibb, the global pharmaceutical giant, said on Friday that it would acquire Karuna Therapeutics, which makes drugs to treat schizophrenia and Alzheimer’s, in an all-cash deal...